Loading patent…
OwnerArmen B. Shanafelt, Jeffrey M. Greve +3inventors
InventorsArmen B. Shanafelt, Jeffrey M. Greve, Gary Jesmok, Kenneth J. Lembach, Gayle D. Wetzel
Estimating the term…
The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
A polypeptide comprising a human interleukin-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over Natural Killer cells.
The human IL-2 mutein of claim 6 wherein said position 88 is substituted with arginine.
A method of selecting IL-2 muteins through evaluation in assays utilizing IL-2Rαβγ in comparison with IL-2Rβγ, wherein the activity of an IL-2 mutein is increased relative to wt IL-2 in one assay preferentially to the other.
Dependencies are inferred from the claim text.